Epigenetic remodeling to improve the efficacy of immunotherapy in human glioblastoma: pre-clinical evidence for development of new immunotherapy approaches

Epigenetic remodeling to improve the efficacy of immunotherapy in human glioblastoma: pre-clinical evidence for development of new immunotherapy approaches

Abstract Background Glioblastoma multiforme (GBM) is a highly aggressive primary brain tumor, that is refractory to standard treatment and to immunotherapy with immune-checkpoint inhibitors (ICI). Noteworthy, melanoma brain metastases (MM-BM), that share the same niche as GBM, frequently respond to...

Full description

Bibliographic Details
Main Authors: Maria Fortunata Lofiego, Francesca Piazzini, Francesca Pia Caruso, Francesco Marzani, Laura Solmonese, Emma Bello, Fabrizio Celesti, Maria Claudia Costa, Teresa Noviello, Roberta Mortarini, Andrea Anichini, Michele Ceccarelli, Sandra Coral, Anna Maria Di Giacomo, Michele Maio, Alessia Covre, The EPigenetic Immune-oncology Consortium Airc (EPICA) investigators
Format: Article
Language:English
Published: BMC 2024-03-01
Series:Journal of Translational Medicine
Subjects:
Glioblastoma
Brain metastases
Immunotherapy
DNA hypomethylating agent
Melanoma
Online Access:https://doi.org/10.1186/s12967-024-05040-x

Internet

https://doi.org/10.1186/s12967-024-05040-x

Similar Items